Singapore HSA Registry: 20,600 Devices, Ownership, and Registrant Concentration

Executive Summary

Singapore's Health Sciences Authority (HSA) maintains one of the most transparent medical device registries in Southeast Asia — the Singapore Medical Device Register (SMDR). As of June 2026, the register lists 20,599 approved medical devices (Class B, C, and D), managed by 859 unique registrants and owned by manufacturers from 225 countries and territories.

Our analysis of the complete public SMDR extract reveals a market defined by two concentric dynamics: product ownership is overwhelmingly foreign (US manufacturers alone hold 37.9% of all registered devices), while the registrant layer — the local entities that hold each device licence and serve as the regulatory interface with HSA — is concentrated among the Singapore subsidiaries of the same multinational device companies. The top 20 registrants control 35.5% of all registrations, and the HHI of 93 signals moderate concentration rather than a lock-in market.

Class B devices dominate at 57.5%, followed by Class C (30.0%) and Class D (11.6%). General Hospital, Cardiovascular, and General & Plastic Surgery are the three largest specialty areas. Annual registration volumes have held steady at approximately 1,000–1,300 new devices per year since 2015, with 2024 reaching a recent high of 1,270 new registrations.

This article breaks down the SMDR by risk class, specialty, product-owner country, registrant concentration, and annual registration trends — giving regulatory strategists and market-access teams a quantitative foundation for Singapore planning.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of the HSA Listing of Registered Medical Devices (public dataset, data.gov.sg, extracted June 2026). The dataset includes 20,599 device registration records with device name, description, GMDN term, medical specialty area, HS code, HSA product code, device class, registration number, registration date, product owner name and address, registrant name and address, importer name and address, model name, and model identifier.

Product-owner country was extracted from the address field (last comma-delimited segment, normalized for common variants). Registrant concentration was computed using standard Herfindahl-Hirschman Index (HHI) methodology. Percentages are calculated against the total relevant denominator (all 20,599 records unless otherwise noted).

Class A devices are exempt from product registration and are excluded from the SMDR; they are not represented in this analysis.

Singapore's Regulatory Framework: Why This Market Matters

Singapore became the first regulatory authority globally to reach WHO's highest classification (Maturity Level 4) for medical device regulation in March 2026, when the World Health Organization recognized HSA as a Listed Authority across all regulatory functions. This designation confirms HSA's processes meet the highest international benchmarks — and makes Singapore an increasingly important reference regulator for the broader ASEAN region.

HSA regulates medical devices under the Health Products Act 2007 and Health Products (Medical Devices) Regulations 2010. The classification system follows the four-tier GHTF framework (Class A through D), and HSA accepts prior approvals from five reference agencies (US FDA, EU Notified Bodies, Health Canada, Australia TGA, and Japan PMDA/MHLW) to qualify for abridged evaluation routes.

In September 2025, HSA and Malaysia's Medical Device Authority (MDA) launched a six-month regulatory reliance pilot programme that allows devices approved by one authority to receive an abridged review pathway from the other. The pilot ran from 1 September 2025 to 28 February 2026 and was deemed successful; on 11 March 2026 the two agencies announced full implementation of the Medical Device Regulatory Reliance Programme, effective from 1 March 2026 — reinforcing Singapore's role as an ASEAN regulatory gateway.

Device Class Distribution

The SMDR's 20,599 registered devices break down as follows:

The Class B majority reflects Singapore's role as a procurement hub for general hospital and surgical supplies that flow through to both domestic healthcare and regional distribution. Class C devices — moderate-to-high risk products requiring full or abridged evaluation — form the next largest segment, consistent with Singapore's advanced hospital infrastructure and demand for implants, pumps, and monitoring equipment.

The 2,569 Class D devices (including combination products) represent the most stringent regulatory tier. Class D devices generally require full evaluation, though those with prior approval from HSA's reference agencies can qualify for abridged or expedited routes that shorten review time.

Medical Specialty Landscape

The 20,599 devices span 27 HSA-recognized medical specialty areas. The top 10 account for 72.4% of all registrations:

General Hospital leads by a wide margin — a broad catch-all category that includes wound care, basic surgical instruments, tubing sets, and general-purpose devices. The concentration of IVD-related specialties (Immunology + Clinical Chemistry = 13.6%) underscores Singapore's importance as an in-vitro diagnostics market. Together with Microbiology (609 devices) and Hematology (530), IVD devices account for roughly 19% of the entire register.

Product Owner Geography: Who Makes Singapore's Devices

The most striking finding is the overwhelming foreign ownership of devices registered in Singapore. Product owners are headquartered in 225 countries and territories, but the distribution is heavily concentrated in a small number of major medtech manufacturing nations:

The top three countries — the United States, Germany, and Japan — account for 57.8% of all registered devices. US-headquartered product owners alone hold more registrations than the next five countries combined.

Singapore-based product owners account for a minority share. The majority of devices are manufactured abroad and imported through the registrant/importer mechanism, consistent with Singapore's role as a small domestic market that punches above its weight as a regional distribution hub.

Top Product Owners

The most prolific product owners are a who's who of global medtech:

Roche and Siemens together account for 678 IVD devices — 3.3% of the entire register. The IVD dominance reflects Singapore's high per-capita diagnostic testing rate and the role of the country's laboratory networks as reference centres for Southeast Asia.

Registrant Concentration: Who Holds the Local Licences

Under Singapore's regulatory framework, every foreign-manufactured device must be registered through a local Registrant — a Singapore-based entity that holds the product licence, manages regulatory correspondence with HSA, and is responsible for post-market obligations. The Registrant is the single most important relationship for market access: registrations can only be transferred with the current Registrant's written consent.

Among 20,599 registered devices, there are 859 unique registrants. But the distribution is skewed toward the Singapore subsidiaries of major multinational device companies:

Concentration metrics:

• Top 5 registrants: 2,810 devices (13.6% of all registrations)
• Top 10 registrants: 4,667 devices (22.7%)
• Top 20 registrants: 7,306 devices (35.5%)
• HHI: 93 (moderate concentration)

The HHI of 93 places this market well below the threshold for high concentration (HHI > 2,500). The registrant landscape is moderately concentrated but competitive — there are hundreds of active registrants, and the top 20 collectively hold just over a third of registrations. For foreign manufacturers, this means there are many registrant options, but the dominant registrants tend to be the in-house Singapore subsidiaries of large multinational medtech companies that serve as their own local licence holders.

Implications for market entry: Foreign manufacturers entering Singapore typically choose between (1) establishing their own Singapore entity as registrant, (2) appointing a third-party regulatory representative, or (3) using a distributor that also serves as registrant. Each option involves trade-offs in control, cost, and flexibility. Because registrations cannot be transferred unilaterally, the choice of registrant is a long-term commercial relationship.

Registration Trends: Steady Growth with a 2024 Surge

Annual registration volumes have been remarkably consistent since 2015, ranging from approximately 950 to 1,270 new devices per year:

Several observations:

• 2024 peak. The 1,270 registrations in 2024 represent the highest annual volume in the dataset, driven by a surge in Class B registrations (811, up 25% from 2023's 649). This may reflect post-pandemic normalisation and increased regional distribution activity.
• Class C and D stability. Higher-risk device registrations have remained relatively stable at 220–360 (Class C) and 109–154 (Class D) per year, suggesting a mature market for regulated medical devices.
• 2022 dip. The 2022 figure of 952 was the lowest since 2017, possibly reflecting a transition period as HSA updated its SHARE (Singapore Health Product Access and Regulatory E-System) digital submission platform.

HSA Registration Fees and Evaluation Timelines

HSA charges mandatory government fees based on device risk class and evaluation route. According to publicly available HSA fee schedules:

Application fees of SGD 560 (approximately USD 435) apply to all classes. Evaluation fees are assessed per product. Fees are government fees only and do not include consulting, dossier preparation, testing, or regulatory representation costs.

For devices with prior reference-agency approval (US FDA, EU, Health Canada, TGA, or Japan PMDA), the abridged evaluation routes can significantly reduce review time. The Immediate Registration route for qualifying Class B devices grants SMDR listing upon successful submission.

Singapore in Context: ASEAN Regulatory Gateway

Singapore's medical device market, while small in population (5.9 million), is disproportionately important for three reasons:

1. WHO Maturity Level 4. HSA's designation as a WHO Listed Authority at the highest maturity level gives Singapore regulatory decisions weight with other regulators in the ASEAN region and beyond.

2. ASEAN CSDT harmonisation. Singapore uses the ASEAN Common Submission Dossier Template (CSDT), meaning a well-prepared Singapore dossier can be adapted for Malaysia, Thailand, Indonesia, the Philippines, and other ASEAN markets with reduced incremental effort.

3. Malaysia-Singapore reliance programme. The regulatory reliance arrangement between HSA and Malaysia's MDA, piloted from September 2025 and made permanent from March 2026, creates a two-country fast track that no competitor in the region currently offers.

4. IMDRF leadership. Singapore hosted the 29th International Medical Device Regulators Forum (IMDRF) meeting in March 2026, reinforcing its position as a global regulatory standard-setter.

For regulatory strategists, these factors make Singapore both a standalone market opportunity and a stepping stone to broader ASEAN access — a "register once, leverage everywhere" proposition that becomes more valuable as regional reliance pathways mature.

Key Takeaways

• 20,599 approved devices across Class B (57.5%), Class C (30.0%), and Class D (12.5%)
• 37.9% of devices are owned by US-headquartered manufacturers; the US, Germany, and Japan together account for 57.8%
• 859 unique registrants with an HHI of 93 — moderate concentration, not a lock-in market
• Top 20 registrants hold 35.5% of all registrations, led by Siemens Healthcare (671) and J&J (636)
• Registration volumes stable at ~1,000–1,300/year since 2015, with 2024 reaching a recent high of 1,270
• General Hospital, Cardiovascular, and IVD are the dominant specialty areas
• HSA's WHO ML4 designation and ASEAN harmonisation make Singapore an increasingly strategic regulatory entry point

Data Source

Analysis sample: HSA Listing of Registered Medical Devices (public dataset, data.gov.sg, extract dated June 2026), 20,599 device registration records. Product-owner country derived from address field normalization. Registrant concentration computed via HHI. All numbers reflect the public register and may differ slightly from HSA's internal records due to timing of data publication.